Glaucoma – Unmet Need – Detailed, Expanded Analysis (US/EU)

Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States and Europe. The majority of glaucoma patients have primary open-angle glaucoma (POAG). Treatment of POAG aims to lower and stabilize IOP; pharmacotherapy is widely used for this purpose. The pharmaceutical market for POAG is broad and highly genericized. Prostaglandin analogues, such as latanoprost and bimatoprost are the long-standing first-class treatment option for POAG due to their demonstrated efficacy, safety, and once-per-day self-administration. Beta blockers such as timolol are widely used as follow-up therapies; other later-line agents include alpha agonists and carbonic anhydrase inhibitors. In 2018, Alcon’s (formerly Aerie’s) first-in-class Rhopressa (netarsudil) received FDA approval, followed in 2019 by its netarsudil / latanoprost FDC, Rocklatan; both agents have since received EMA approval in Europe. The current POAG pipeline is active and includes novel agents as well as alternative formulations of existing therapies with differing administration requirements. By examining the key treatment drivers and greatest areas of unmet need in POAG prescribing, this content presents the opportunities in this space.


  • What are the treatment drivers and goals for POAG?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for POAG?
  • What are the prevailing areas of unmet need and opportunity in POAG?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new POAG drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European ophthalmologists fielded in July 2023

Key companies: AbbVie / Allergan, Pfizer, Novartis, Merck & Co, Viatris, Théa

Key drugs: Xalatan, Lumigan, timolol, Alphagan, Azopt, Combigan, Cosopt

Table of contents

launch Related Market Assessment Reports